**PRIOR AUTHORIZATION POLICY**

**POLICY:** Hereditary Angioedema – Kalbitor® (ecallantide injection for subcutaneous use – Dyax)

**TAC APPROVAL DATE:** 08/07/2019

---

**OVERVIEW**
Kalbitor, a plasma kallikrein inhibitor, is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients ≥ 12 years of age.¹ Potentially serious hypersensitivity reactions, including anaphylaxis, have occurred in patients treated with Kalbitor. Kalbitor should only be administered by a healthcare professional with appropriate medical support to manage anaphylaxis and HAE.

**Disease Overview**
HAE due to C1 esterase inhibitor (C1-INH) deficiency has two subtypes: HAE type I and HAE type II. HAE diagnosis can be confirmed by measuring functional C1-INH protein levels (usually < 50% of normal in patients with HAE), C4 levels, and C1-INH antigenic levels.²,³ Patients with HAE type I have low C4 and C1-INH antigenic protein levels, along with low levels of functional C1-INH protein. Patients with HAE type II have low C4 and functional C1-INH protein level, with a normal or elevated C1-INH antigenic protein level. C1-INH replacement therapies are appropriate for both HAE type I and type II.

Patients with the third type of HAE, currently called HAE with normal C1-INH (previously referred to as HAE type III), have normal C4 and C1-INH antigenic protein levels.² The exact cause of HAE with normal C1-INH has not been determined. There are no randomized or controlled clinical trial data available with any therapy for use in HAE with normal C1-INH.⁴,⁵ The consensus panel notes that until data from randomized controlled studies become available, no firm recommendations regarding the treatment of HAE with normal C1-INH can be made.⁴

**Guidelines**
Per the World Allergy Organization/European Academy of Allergy and Clinical Immunology guidelines (2017), all attacks should be considered for acute treatment; treatment is mandatory for any attack potentially affecting the upper airway.³ Attacks should be treated as early as possible. Self-administration at home facilitates earlier response. The guidelines recommend C1-INH products (Cinryze, Berinert, or Ruconest), Kalbitor, or icatibant (Firazyr, generics) as first-line treatment options. Androgens and antifibrinolytics are not effective as acute treatment. Patients should carry acute treatment with them at all times and should have enough supply on hand for treatment of two attacks. Other guidelines from the US Hereditary Angioedema Association Medical Advisory Board (2013) and a practice parameter update from a Joint Task Force (2013) have similar recommendations.⁶,⁷

**POLICY STATEMENT**
Prior authorization is recommended for prescription benefit coverage of Kalbitor. Because of the specialized skills required for the evaluation and diagnosis of patients treated with Kalbitor, approval requires Kalbitor to be prescribed by or in consultation with a physician who specializes in the condition being treated. All approvals are provided for the duration noted below.
Hereditary Angioedema – Kalbitor PA Policy
Page 2

**Documentation:** Documentation will be required where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes, laboratory records, and prescription claims records.

**Automation:** None.

**Recommended Authorization Criteria**
Coverage of Kalbitor is recommended in those who meet the following criteria:

**FDA-Approved Indications**

1. **Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II] – Treatment of Acute Attacks.** Approve Kalbitor for the duration noted if the patient meets one of the following criteria (A or B):
   A) **Initial therapy.** Approve for 1 year if the patient meets both of the following criteria (i and ii):
      i. The patient has HAE type I or type II as confirmed by the following diagnostic criteria (a and b):
         a) The patient has low levels of functional C1-INH protein (< 50% of normal) at baseline, as defined by the laboratory reference values [documentation required]; AND
         b) The patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values [documentation required]; AND
      ii. The medication is prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.
   B) **Patients who have treated previous acute HAE attacks with Kalbitor.** Approve for 1 year if the patient meets all of the following criteria (i, ii, and iii):
      i. The patient has treated previous acute HAE type I or type II attacks with Kalbitor [documentation required to confirm HAE type I or type II diagnosis]; AND
      ii. According to the prescriber, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with Kalbitor treatment; AND
      iii. The medication is prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.

**Conditions Not Recommended for Approval**
Kalbitor has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. **Hereditary Angioedema (HAE) Prophylaxis.** Data are not available and Kalbitor is not approved by the FDA for the prophylaxis of HAE attacks.

2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.
REFERENCES


HISTORY

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes*</th>
<th>TAC Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual revision</td>
<td>Added “Due to C1 Inhibitor (C1INH) Deficiency [Type I or Type II]” to HAE indication description. Added documentation requirement for initial therapy laboratory diagnostic criteria and for continuing therapy to confirm diagnosis. Added “at baseline” after laboratory diagnostic criteria. Added criteria confirming favorable clinical response for patients continuing therapy. For patients continuing Kalbitor, added specialist physician criteria similar to initial therapy.</td>
<td>11/15/2017</td>
</tr>
<tr>
<td>Early annual revision</td>
<td><strong>All Indications:</strong> Approval duration decreased to 1 year from 3 years.</td>
<td>10/03/2018</td>
</tr>
<tr>
<td>Annual revision</td>
<td><strong>All Indications:</strong> “Prescribing physician” changed to “prescriber” throughout policy.</td>
<td>08/07/2019</td>
</tr>
</tbody>
</table>

*TAC – Therapeutic Assessment Committee; *For a further summary of criteria changes, refer to respective TAC minutes available at: http://esidepartments/sites/Dep043/Committees/TAC/Forms/AllItems.aspx.